J Korean Med Sci.  2009 Jun;24(3):511-512. 10.3346/jkms.2009.24.3.511.

Clarithromycin Susceptibility Testing of Mycobacterium avium Complex Using 2,3-Diphenyl-5-thienyl-(2)-tetrazolium Chloride Microplate Assay with Middlebrook 7H9 Broth

• Park YK
• Koh WJ
• Kim SO
• Shin S
• Kim BJ
• Cho SN
• Lee SM
• Chang CL

• KMID: 1779172
• DOI: http://doi.org/10.3346/jkms.2009.24.3.511

Abstract

A series of 119 Mycobacterium avium complex isolates were subjected to clarithromycin susceptibility testing using microplates containing 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride (STC). Among 119 isolates, 114 (95.8%) were susceptible to clarithromycin and 5 were resistant according to the new and the standard method. STC counts the low cost and reduces the number of procedures needed for susceptibility testing.

Keyword

Tetrazolium; Microtiter Method; Mycobacterium Avium Complex; Clarithromycin; Susceptibility Testing

MeSH Terms

Clarithromycin/*pharmacology
Culture Media
Humans
Microbial Sensitivity Tests/*methods
Mycobacterium avium Complex/*drug effects/isolation & purification
Tetrazolium Salts/*chemistry

Reference

1. Jeon K, Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, Lee NY, Park YK, Bai GH. Recovery rate of NTM from AFB smear-positive sputum specimens at a medical centre in South Korea. Int J Tuberc Lung Dis. 2005. 9:1046–1051.

2. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest. 2006. 129:341–348.

3. Heifets LB. Clarithromycin against Mycobacterium avium complex infections. Tuber Lung Dis. 1996. 77:19–26.

4. Clinical and Laboratory Standards Institute. CLSI document M24-A. Susceptibility testing of mycobacteria, Norcardiae, and Other Aerobic Actinomycetes; Approved Standard. 2003. Wayne, Pa. USA: CLSI.

5. Shin JH, Choi JC, Lee JN, Kim HH, Lee EY, Chang CL. Evaluation of a colorimetric antifungal susceptibility test by using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride. Antimicrob Agents Chemother. 2004. 48:4457–4459.

6. Lee SM, Kim J, Jeong J, Park YK, Bai GH, Lee EY, Lee MK, Chang CL. Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing. J Korean Med Sci. 2007. 22:784–790.

7. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997. 156:S1–S25.

8. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007. 175:367–416.

9. Kawata N, Kawahara S, Tada A, Takigawa N, Shibayama T, Soda R, Takahashi K. Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM. Kekkaku. 2006. 81:329–335.

10. Gomez-Flores R, Gupta S, Tamez-Guerra R, Mehta RT. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method. J Clin Microbiol. 1995. 33:1842–1846.